Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization for its COVID-19 vaccine by May.
What percentage of a population needs to be immune in order to achieve herd immunity is a matter of debate among scientists and public health officials.
To facilitate its goal of building an industry-leading gene therapy company focused on rare CNS diseases, Sio has made it a priority to interact with patient organizations to determine their primary objective, whether that be stability or a cure.
The company has agreed to deliver 100 million doses of the vaccines by the end of June.
After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.
On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.
It was another busy week for clinical trial news. Here’s a look.
Bristol Myers Squibb and bluebird bio said data from the Phase II KarMMa study evaluating the safety and efficacy of ide-cel (idecabtagene vicleucel) met the primary endpoint of overall survival and the key secondary endpoint of complete response rate.
As the vaccines against COVID-19 are being rolled out worldwide, numerous studies are being conducted to evaluate how the vaccines do under less controlled situations. Here’s a look.
As scientists and vaccine manufacturers continue to test their products against the variants, researchers are seeing new variants cropping up that originated in the U.S.